Outlawed terrorist groups - Balochistan Liberation Army (BLA), including its Majeed Brigade, and Tehrik-e Taliban Pakistan (TTP - have "close coordination", according to a United Nations Security ...

The United Nations Security Council report pointed out that "some BLA attacks showed a high degree of complexity and brutality", citing Jaffar Express' dramatic hijacking in Pakistan's Balochistan ...

Qure (NASDAQ:QURE) is one of the biotech stocks to buy according to Wall Street analysts. Earlier on June 2, uniQure provided a regulatory update on AMT-130, which is the company’s investigational ...

The Baloch Army (BLA) has claimed responsibility for an attack on a bus carrying Pakistan Army personnel in the Quetta and Kalak regions of Pakistan. According to the claims, 29 soldiers have been ...

Amid the dusty plateaus and strategic choke points of Balochistan, a covert conflict is rapidly intensifying — one that escapes international scrutiny but deeply threatens the region’s stability.

Quetta: Pakistan Army Military Intelligence officer, Major Anwar Kakar, was reportedly killed in a powerful blast in Quetta.

Replimune Group, Inc – a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies – ...

Among reasons for the rejection, the agency cited a lack of US patient representation in the STARGLO trial assessing ...

Replimune (NASDAQ:REPL) stock surges as Cantor Fitzgerald upgrades, citing improved odds for approval of its lead drug after an FDA leadership change. Read more here.

The Baloch Liberation Army has claimed responsibility for a bomb blast in Quetta that killed Major Anwar Kakar, a senior ...

The FDA has accepted for priority review the resubmitted BLA for tabelecleucel to treat patients 2 years of age and older with EBV+ PTLD who have received at least 1 prior therapy.

Key Takeaways The FDA accepted a Priority Review BLA for RP1 and Opdivo in advanced melanoma, with a PDUFA date of July 22, 2025. The BLA is supported by IGNYTE trial data, focusing on patients with ...